Myocardial Ischemia Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Myocardial Ischemia Market From 2025 To 2034?

The market size for myocardial ischemia has shown robust growth in recent years. It is expected to expand from $0.79 billion in 2024 to $0.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.7%. The growth observed in the past can be attributed to the increased use of telemedicine and remote monitoring, the development of new reperfusion therapies for MI, and a rise in instances of obesity, high blood pressure, and heart attacks.

The myocardial ischemia market size is projected to experience robust expansion over the next few years. It is anticipated to grow to $1.08 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.4%. This growth during the forecast period can be attributed to the prevalence of various heart-related illnesses, increasing public understanding of cardiovascular diseases, continuously evolving lifestyles, a rise in diabetes cases, and growing healthcare expenditure. Significant trends in the forecast period encompass the adoption of myocardial ischemia treatments, enhanced healthcare infrastructures, advancements in treatment options, the integration of digital health solutions, and the introduction of cardiac rehabilitation programs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16488&type=smp

Which Factors And Drivers Are Influencing The Myocardial Ischemia Market In 2025?

The escalating occurrence of diabetes is anticipated to stimulate the growth of the myocardial ischemia market moving forward. Diabetes refers to a collection of metabolic conditions characterized by the body’s impaired capacity to produce or effectively utilize insulin, a hormone from the pancreas crucial for blood sugar regulation. This increasing incidence of diabetes is primarily attributed to factors like obesity, severe obesity, insufficient physical activity, and genetic predispositions. The expanding prevalence of diabetes, in turn, contributes to a higher rate of myocardial ischemia, consequently generating greater demand for diagnostic, therapeutic, and management solutions for the condition. For example, in April 2023, a report from The British Diabetic Association, a UK-based diabetes charity, stated that 4.3 million individuals in the UK had been diagnosed with diabetes. Registration data for 2021-22 further revealed an increase of 148,951 cases compared to 2020-21. Moreover, over 2.4 million people in the UK are at a significant risk of developing type 2 diabetes. The rising incidence of diabetes is therefore a significant driver for the growth of the myocardial ischemia market.

What Are The Major Segment Categories Driving The Myocardial Ischemia Market Growth?

The myocardial ischemiamarket covered in this report is segmented –

1) By Type: Symptomatic; Asymptomatic

2) By Treatment And Diagnosis: Diagnosis; Treatment

3) By End User: Hospitals And Clinics; Diagnostic Centers; Ambulatory Surgery Centers

Subsegments:

1) By Symptomatic: Acute Myocardial Ischemia; Chronic Myocardial Ischemia; Stable Angina; Unstable Angina

2) By Asymptomatic: Silent Myocardial Ischemia; Exercise-Induced Asymptomatic Ischemia

Which Ongoing Trends Are Expected To Shape The Myocardial Ischemia Market Outlook?

Major companies within the myocardial ischemia market are actively developing innovative drugs, such as Lodoco (colchicine), with the goal of reducing inflammation and decreasing the risk of cardiovascular events in patients suffering from coronary artery disease. Lodoco is prescribed to mitigate the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients who have established atherosclerotic disease or possess multiple risk factors for cardiovascular disease. For example, in June 2023, Agepha Pharma, a US-based pharmaceutical company, introduced Lodoco (colchicine) following its approval by the Food and Drug Administration, a US-based government agency. This marks the initial FDA-approved therapy designed to target cardiovascular inflammation. Its approval is substantiated by data from the LoDoCo2 trial, which demonstrated a 31% relative reduction in the risk of cardiovascular events for patients administered colchicine 0.5 mg once daily when compared to a placebo. Lodoco is thereby utilized to lower the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients presenting with existing atherosclerotic disease or several cardiovascular risk factors.

Which Leading Players Are Enhancing Their Myocardial Ischemia Market Presence Worldwide?

Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Novo Nordisk A/S, Medtronic Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Baxter International Inc., Regeneron Pharmaceuticals Inc., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

What Are The Key Regional Factors Influencing The Myocardial Ischemia Market Growth?

North America was the largest region in the myocardial ischemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Myocardial Ischemia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16488&type=smp

Browse Through More Reports Similar to the Global Myocardial Ischemia Market 2025, By The Business Research Company

Myocardial Infarction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report

Critical Limb Ischemia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/critical-limb-ischemia-global-market-report

Cardiac Pacemakers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795